Daily Briefing – May 23: Dow closes at record 50,579 for its 8th straight weekly gain, Warsh takes the Fed helm with a hawkish tone, oil slides on Iran progress, SoftBank/ARM amplify Nvidia momentum, tariff ruling adds legal fog, while BIIB PDUFA slips to August and MRVL/CRM/SNOW define the Tuesday-open playbook
The May 23 briefing is a Memorial Day long-weekend edition, with markets closed Monday May 26 and reopening Tuesday May 27. The week ended with the Dow setting a fresh record at 50,579.70 (+294 points, +0.58%), the S&P 500 notching its eighth consecutive weekly gain at 7,473.47 (+0.37%), and the Nasdaq securing its seventh weekly advance in eight weeks at 26,343.97 (+0.19%). The most important structural shift came off-screen: Kevin Warsh was sworn in as the 17th Fed chair on May 22 with a clearly hawkish orientation — rates are expected to stay on hold through all of 2026, the 30-year Treasury yield has moved above 5%, and CME FedWatch is beginning to price a potential hike by year-end, which now shadows every high-multiple trade in the market. Oil was the week’s biggest macro surprise: Brent fell 5% and WTI lost more than 8% after Trump called off airstrikes on Iran and Secretary Rubio cited “good signs” in talks, though enriched uranium stockpiles and Strait of Hormuz access remain unresolved sticking points. In AI, the Nvidia earnings aftershock flowed directly into SoftBank — up 20% Thursday and 11.9% Friday — adding over $61 billion in market cap in two sessions through its stake in ARM Holdings. One critical calendar update: the FDA extended its review of Biogen/Eisai’s Leqembi IQLIK by three months due to a major sBLA amendment, moving the PDUFA date from May 24 to August 24, 2026. For next week: MRVL, CRM, SNOW, and SNPS report Wednesday, and Consumer Confidence prints Tuesday.
- NVDA— Slipped roughly -1.77% despite a record Q1 (Data Center $75.2B, Q2 guide ~$91B, $80B buyback authorization): the market had already priced perfection in, and Friday’s session confirmed that even the best numbers can meet profit-taking when expectations are extremeAI Semis
- SFTBY / ARM— SoftBank was the week’s clearest AI momentum trade: +20% Thursday, +11.9% Friday, more than $61 billion in market cap added in two sessions via its controlling stake in ARM Holdings, whose chip designs power the AI servers running alongside Nvidia GPUsAI Momentum
- WARSH / FED— Kevin Warsh sworn in May 22 as the 17th Fed chair with a hawkish policy bias: rates expected on hold through all of 2026, 30-year Treasury yield above 5%, and CME FedWatch beginning to price a potential rate hike by year-end — a structural headwind for every high-multiple growth tradeFed / Rates
- OIL / IRAN— Brent fell 5% and WTI lost more than 8% for the week after Trump suspended airstrikes on Iran and Rubio cited “good signs” in nuclear talks. Key sticking points remain: enriched uranium stockpiles and Strait of Hormuz tolls. Energy executives warn full supply normalization may not occur before 2027Oil / Geo
- Tariffs / Court ruling— The Court of International Trade ruled the Section 122 10% global tariffs invalid (effective February 24, 2026). Legal uncertainty remains high: the average effective tariff rate was 11.8% in April, but companies cannot plan supply chains on stable ground until the legal and executive landscape consolidatesTrade Policy
- GOOG / GOOGL— Alphabet updated its 2026 capital expenditure guidance to $180–190 billion, entirely directed at AI infrastructure. The figure confirms the AI capex cycle remains fully intact and that demand for GPUs, advanced CPUs, networking and data-center capacity is not slowingAI Capex
- BIIB / ESALY— Critical calendar update: FDA extended its review of Leqembi IQLIK by three months following a major amendment to the sBLA. The new PDUFA action date is now August 24, 2026. The May 24 date is no longer an immediate catalyst for Biogen or EisaiPDUFA Reset
- CPRX— Catalyst Pharmaceuticals to be acquired by Angelini Pharma at $31.50 per share in cash, for a total equity value of approximately $4.1 billion (announced May 7). The deal signals that big pharma continues to target validated commercial-stage assets in specialty neurologyM&A Biotech
- MRVL / CRM / SNOW / SNPS— The earnings core of the post-Memorial Day week: Marvell Technology, Salesforce, Snowflake, and Synopsys all report Wednesday May 27, delivering the next real-time read on AI infrastructure, enterprise software adoption, and advanced chip demandEarnings Watch
- SOX / SOXX— The Philadelphia Semiconductor Index is up 65% year-to-date; the SOXX ETF has gained 54.7%. Veteran analysts are drawing parallels to 1999-2000 and warning of potential 25-30% corrections, not denying the AI thesis but flagging that valuations have detached from near-term fundamentalsSemis / Risk
- Warsh hawkish = multiple compression risk— With rates on hold (or potentially rising) through 2026 and the 30-year yield above 5%, AI, biotech, and quantum names trading at high multiples become more vulnerable to any adverse macro data or geopolitical headlineFed
- Oil: relief or head-fake— The Brent and WTI weekly declines are real but incomplete. A US-Iran deal could bring meaningful new supply; a breakdown in talks can reverse the move quickly, with immediate pass-through to consumer prices, margins, and inflation expectationsOil
- Tariff legal fog— The Section 122 ruling does not close the tariff dossier: executive appeals, new orders, and WTO filings remain on the table. Businesses cannot rebuild supply chains on stable assumptions until the legal and policy picture clarifies durablyTrade
- AI capex cycle is the strongest confirmation— Nvidia’s $91B Q2 guide, Alphabet’s $180-190B capex, and SoftBank’s $61B market cap gain in two days all point in the same direction: the infrastructure build is real. But AI stocks already price a lot of this, and the market is growing more selectiveAI
- Earnings season winding down— Post-Memorial Day focus shifts to macro data and the Wednesday software/semi reports. CRM, MRVL, SNOW, and SNPS will set the tone for June, and any guidance miss in enterprise software could revive Intuit-style selloff dynamicsEarnings
- Long weekend = headline risk window— Three days of market closure with Iran talks active, Warsh Fed in its first week, and tariff legal uncertainty unresolved: Tuesday’s futures open could gap meaningfully in either direction depending on weekend developmentsTape Risk
- Consumer back under scrutiny— May Consumer Confidence (Tuesday) is the first meaningful macro print post-Memorial Day and will be read directly alongside Walmart’s prior-week warning on fuel costs, defensive shopper behavior, and margin pressureConsumer
- SOX bubble watch is active— A semiconductor index up 65% YTD historically amplifies both rallies and corrections with outsized speed. The magnitude of the move demands higher discipline: tighter stops, reduced sizing, and a preference for names with near-term fundamental catalystsRisk
Run-Up Biotech Masterclass
Learn how to read biotech catalysts, trial results and FDA decisions with a practical framework.
OpenBiotech Catalyst Calendar
Track FDA events, clinical readouts and biotech catalysts with a practical event-driven tool.
Open ArchiveBrowse the Blog & Archive
Explore articles, biotech deep dives, market notes, reports and archived sector content.
Open Reality CheckBiotech Trading Without the Fairy Tales
A grounded piece on risk, catalysts, dilution, volatility and biotech trading reality.
Open 2026 WatchlistThe New Era – Space, Defense & AI
A thematic watchlist built around military spending, strategic technology and AI-linked trends.
Open BriefingSPACE AI DEFENCE
A thematic briefing at the intersection of defense, space infrastructure and AI.
Open Top ListTop 10 Defense-Tech Stocks to Watch
A focused list built around defense technology, drones and strategic systems.
Open Top ListTop 5 U.S. Airlines Watchlist
A practical watchlist for pricing power, fuel sensitivity, travel demand and macro tone.
Open Top ListTop 5 Cruise Lines Watchlist
A leisure-focused list centered on major cruise operators and pricing-driven sentiment.
Open- Natera, Inc. (Nasdaq: $NTRA): A Full Deep Dive Into the cfDNA Platform, Signatera Momentum, FDA CDx Validation, Fetal Focus, Prospera and the Next Catalyst Stack
- Immuneering Corporation (Nasdaq: $IMRX): ASCO Survival Update Turns Atebimetinib Into a High-Stakes Pancreatic Cancer Story
- Ebola Preparedness Trade: $GOVX, $CODX and $RDHL Revisit Vaccines, Diagnostics and Antiviral Readiness
- Silexion Therapeutics Corp. (Nasdaq: $SLXN): KRAS-Driven Pancreatic Cancer, SIL204, and the Very Thin Balance-Sheet
- MetaVia Inc. (Nasdaq: $MTVA): ADA Late-Breaking Posters, DA-1726 Obesity Signal, and the Financing Wall Behind the Run
- Regeneron Pharmaceuticals (Nasdaq: $REGN): Melanoma Setback Reopens the 2026 Growth Debate
- BriaCell Therapeutics Corp. (Nasdaq: $BCTX): Phase 3 Breast Cancer, ASCO 2026 And A Rapid Pipeline Expansion
- Fortress Biotech (Nasdaq: $FBIO): Q1 2026 Turns the Story Into a Portfolio-Model Test
- Microbot Medical (Nasdaq: $MBOT): First LIBERTY Revenue, Real Doctors and the Small-Cap Robotics Test
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and sector rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 to get 10% OFF your first paid period.
No credit card required to start. Apply SAVE10 when upgrading.
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with professional charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day and swing traders.
Multi-broker workflow + customizable layouts in one platform.









